Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McMaster University

$27,000.00

A Therapeutic Strategy Targeting Lipid Metabolism: Discovery of Novel Inhibitors That Cross the Blood–Brain Barrier for the Treatment of Medulloblastoma

FY 2025-26

Summary
Medulloblastoma (MB) is the most common malignant pediatric brain cancer. Among its subgroups, Group 3 (G3) has the worst prognosis, with many patients dying due to treatment resistance and metastasis. Current standard-of-care (SoC)—surgery, chemotherapy and craniospinal irradiation—is highly toxic, leaving survivors with permanent neurological effects, highlighting the need for safer, targeted therapies. Cancer cells often rewire metabolic pathways, including lipid production. Using untargeted lipidomics, we compared the lipid profiles of G3-MB with normal neural stem cells, their proposed cell of origin. G3-MB displayed reduced fatty acid saturation, implicating dysregulation of the de novo lipid (DNL) synthesis pathway. Our genome-wide CRISPR knockout screen also revealed DNL enzymes as essential for MB survival, and their gene expression increased at relapse in our patient-derived xenograft (PDX) models. We identified Stearoyl-CoA Desaturase-1 (SCD1), a key DNL enzyme, as a prognostic marker; inhibiting SCD1 with small molecules or genetic approaches selectively impaired tumour growth. However, current SCD1 inhibitors show limited efficacy in vivo due to poor blood-brain barrier (BBB) penetration. To overcome this, we aim to design novel, potent, and BBB-penetrant SCD1 inhibitors. In collaboration with the Uehling Lab (Ontario Institute for Cancer Research) who will synthesize candidate compounds, we will assess how effectively they block SCD1 activity in G3-MB models. Lead compounds will advance to preclinical evaluation in PDX models. Targeting this lipid synthesis pathway offers strong therapeutic promise, may enhance SoC response, and could benefit other central nervous system cancers and neurodegenerative diseases.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572829
Name
Korman Tiegan E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Therapeutic Strategy Targeting Lipid Metabolism: Discovery of Novel Inhibitors That Cross the Blood–Brain Barrier for the Treatment of Medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Blood–Brain Barrier Permeability; Drug Discovery; Lipid Metabolism; Medulloblastoma; Neuro-Oncology; Pediatric Cancer; Small Molecule Inhibitors; Targeted Therapy
Abstract
Medulloblastoma (MB) is the most common malignant pediatric brain cancer. Among its subgroups, Group 3 (G3) has the worst prognosis, with many patients dying due to treatment resistance and metastasis. Current standard-of-care (SoC)—surgery, chemotherapy and craniospinal irradiation—is highly toxic, leaving survivors with permanent neurological effects, highlighting the need for safer, targeted therapies. Cancer cells often rewire metabolic pathways, including lipid production. Using untargeted lipidomics, we compared the lipid profiles of G3-MB with normal neural stem cells, their proposed cell of origin. G3-MB displayed reduced fatty acid saturation, implicating dysregulation of the de novo lipid (DNL) synthesis pathway. Our genome-wide CRISPR knockout screen also revealed DNL enzymes as essential for MB survival, and their gene expression increased at relapse in our patient-derived xenograft (PDX) models. We identified Stearoyl-CoA Desaturase-1 (SCD1), a key DNL enzyme, as a prognostic marker; inhibiting SCD1 with small molecules or genetic approaches selectively impaired tumour growth. However, current SCD1 inhibitors show limited efficacy in vivo due to poor blood-brain barrier (BBB) penetration. To overcome this, we aim to design novel, potent, and BBB-penetrant SCD1 inhibitors. In collaboration with the Uehling Lab (Ontario Institute for Cancer Research) who will synthesize candidate compounds, we will assess how effectively they block SCD1 activity in G3-MB models. Lead compounds will advance to preclinical evaluation in PDX models. Targeting this lipid synthesis pathway offers strong therapeutic promise, may enhance SoC response, and could benefit other central nervous system cancers and neurodegenerative diseases.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Korman, Tiegan E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~